LOUISE HOWE

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. pmc Identification of PADI2 as a potential breast cancer biomarker and therapeutic target
    John L McElwee
    Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, 122 Hungerford Hill Road, Ithaca, NY 14853, USA
    BMC Cancer 12:500. 2012
  2. ncbi request reprint Rexinoids and breast cancer prevention
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Cornell Medical College, and Strang Cancer Research Laboratory, New York, New York 10065, USA
    Clin Cancer Res 13:5983-7. 2007
  3. pmc Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Medical College of Cornell University, York Avenue, New York, New York 10021, USA
    Breast Cancer Res 9:210. 2007
  4. ncbi request reprint HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Medical College of Cornell University, NY, USA
    Cancer Res 65:10113-9. 2005
  5. ncbi request reprint Cyclooxygenase-2: a target for the prevention and treatment of breast cancer
    L R Howe
    Strang Cancer Research Laboratory, Rockefeller University, Box 231, 1230 York Avenue, New York, New York 10021, USA
    Endocr Relat Cancer 8:97-114. 2001
  6. ncbi request reprint COX-2 inhibitors for the prevention of breast cancer
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, New York, USA
    J Mammary Gland Biol Neoplasia 8:31-43. 2003
  7. ncbi request reprint Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer Res 62:5405-7. 2002
  8. ncbi request reprint Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer Res 63:1906-13. 2003
  9. ncbi request reprint HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism
    Kotha Subbaramaiah
    Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Cancer Res 66:5504-11. 2006
  10. pmc Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland
    Kotha Subbaramaiah
    Department of Medicine and Weill Cornell Cancer Center, New York, NY 10065, USA
    Cancer Prev Res (Phila) 4:329-46. 2011

Research Grants

  1. Combination Chemoprevention of ER-Negative Breast Cancer
    LOUISE HOWE; Fiscal Year: 2004
  2. Aspirin for Breast Cancer Prevention
    LOUISE HOWE; Fiscal Year: 2006
  3. Beta-Catenin/TCF Signaling in Breast Cancer
    Louise R Howe; Fiscal Year: 2010

Collaborators

Detail Information

Publications18

  1. pmc Identification of PADI2 as a potential breast cancer biomarker and therapeutic target
    John L McElwee
    Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, 122 Hungerford Hill Road, Ithaca, NY 14853, USA
    BMC Cancer 12:500. 2012
    ..Thus, the goals of this study were to examine whether PADI2 plays a role in mammary tumor progression, and whether the inhibition of PADI activity has anti-tumor effects...
  2. ncbi request reprint Rexinoids and breast cancer prevention
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Cornell Medical College, and Strang Cancer Research Laboratory, New York, New York 10065, USA
    Clin Cancer Res 13:5983-7. 2007
  3. pmc Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Medical College of Cornell University, York Avenue, New York, New York 10021, USA
    Breast Cancer Res 9:210. 2007
    ....
  4. ncbi request reprint HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Medical College of Cornell University, NY, USA
    Cancer Res 65:10113-9. 2005
    ..This finding may help to explain the reduced risk of breast cancer associated with regular use of nonsteroidal anti-inflammatory drugs...
  5. ncbi request reprint Cyclooxygenase-2: a target for the prevention and treatment of breast cancer
    L R Howe
    Strang Cancer Research Laboratory, Rockefeller University, Box 231, 1230 York Avenue, New York, New York 10021, USA
    Endocr Relat Cancer 8:97-114. 2001
    ..Clinical trials will be needed to determine whether COX-2 inhibition represents a useful approach to preventing or treating human breast cancer...
  6. ncbi request reprint COX-2 inhibitors for the prevention of breast cancer
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, New York, USA
    J Mammary Gland Biol Neoplasia 8:31-43. 2003
    ..Thus, selective COX-2 inhibitors offer considerable promise for the prevention and treatment of human breast cancer...
  7. ncbi request reprint Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer Res 62:5405-7. 2002
    ..These results strengthen the rationale for developing clinical trials to determine whether selective Cox-2 inhibitors possess anticancer properties in humans at risk for breast cancer...
  8. ncbi request reprint Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer Res 63:1906-13. 2003
    ....
  9. ncbi request reprint HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism
    Kotha Subbaramaiah
    Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Cancer Res 66:5504-11. 2006
    ..Collectively, our data indicate that COX-2 is the functional intermediate linking HER-2/neu and aromatase and suggest that inhibitors of PGE(2) synthesis will suppress estrogen biosynthesis in breast tissue...
  10. pmc Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland
    Kotha Subbaramaiah
    Department of Medicine and Weill Cornell Cancer Center, New York, NY 10065, USA
    Cancer Prev Res (Phila) 4:329-46. 2011
    ..The presence of CLS may be a biomarker of increased breast cancer risk or poor prognosis...
  11. ncbi request reprint A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer
    Louise R Howe
    Departments of Cell and Developmental Biology and Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Oncol 29:111-9. 2002
    ..Clinical trials are warranted to define the role of selective COX-2 inhibitors in the prevention and treatment of cancer...
  12. ncbi request reprint Wnt signaling and breast cancer
    Louise R Howe
    Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, New York, USA
    Cancer Biol Ther 3:36-41. 2004
    ..This review summarizes the current evidence implicating Wnt/beta-catenin signaling in breast cancer and discusses several possible mechanisms by which the pathway may become activated...
  13. ncbi request reprint The role of COX-2 in breast and cervical cancer
    Andrew J Dannenberg
    Department of Medicine, Weill Medical College of Cornell University, Strang Cancer Research Laboratory, New York, N Y, USA
    Prog Exp Tumor Res 37:90-106. 2003
  14. pmc Pea3 transcription factors and wnt1-induced mouse mammary neoplasia
    Rebecca Baker
    Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, New York, USA
    PLoS ONE 5:e8854. 2010
    ..Furthermore, this study provides evidence for a protumorigenic role of PEA3 factors in breast neoplasia, and supports targeting the PEA3 transcription factor family in breast cancer...
  15. ncbi request reprint Extracellular matrix-induced cyclooxygenase-2 regulates macrophage proteinase expression
    K M Faisal Khan
    Department of Pathology and Laboratory Medicine, Joan and Sanford I Weill Medical College, Cornell University, New York, New York 10021, USA
    J Biol Chem 279:22039-46. 2004
    ....
  16. pmc Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize beta-catenin independently of Frizzled proteins
    Keith Brennan
    Strang Cancer Research Laboratory at The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Oncogene 23:4873-84. 2004
    ..In light of these models, our data imply that LRP5/6/Arrow proteins constitute the distal signal-initiating component of these receptors. The results also support the notion that LRP5/6 are candidate oncogenes...
  17. pmc Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs
    Louise R Howe
    J Natl Cancer Inst 100:1420-3. 2008
  18. ncbi request reprint Germline mutations of AXIN2 are not associated with nonsyndromic colorectal cancer
    Paolo Peterlongo
    Hum Mutat 25:498-500. 2005

Research Grants5

  1. Combination Chemoprevention of ER-Negative Breast Cancer
    LOUISE HOWE; Fiscal Year: 2004
    ..The results of this study will provide the basis for evaluating this combination approach in women at high risk for breast cancer. ..
  2. Aspirin for Breast Cancer Prevention
    LOUISE HOWE; Fiscal Year: 2006
    ..abstract_text> ..
  3. Beta-Catenin/TCF Signaling in Breast Cancer
    Louise R Howe; Fiscal Year: 2010
    ..Positive results in our study would lay the foundation for evaluating the utility of such beta-catenin/TCF antagonists for preventing human breast cancer. ..